- Home
- WHF vs TIL Comparison
WHF vs TIL Comparison
Compare WHF & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WHF
- TIL
- Stock Information
- Founded
- WHF 2011
- TIL 2018
- Country
- WHF United States
- TIL United States
- Employees
- WHF 3
- TIL N/A
- Industry
- WHF Finance Companies
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- WHF Finance
- TIL Health Care
- Exchange
- WHF Nasdaq
- TIL Nasdaq
- Market Cap
- WHF 162.2M
- TIL 177.1M
- IPO Year
- WHF 2012
- TIL 2021
- Fundamental
- Price
- WHF $6.90
- TIL $18.16
- Analyst Decision
- WHF Hold
- TIL Strong Buy
- Analyst Count
- WHF 4
- TIL 5
- Target Price
- WHF $9.17
- TIL $100.67
- AVG Volume (30 Days)
- WHF 200.3K
- TIL 184.6K
- Earning Date
- WHF 11-06-2025
- TIL 11-12-2025
- Dividend Yield
- WHF 25.50%
- TIL N/A
- EPS Growth
- WHF N/A
- TIL N/A
- EPS
- WHF 0.15
- TIL N/A
- Revenue
- WHF $81,499,000.00
- TIL N/A
- Revenue This Year
- WHF N/A
- TIL N/A
- Revenue Next Year
- WHF N/A
- TIL N/A
- P/E Ratio
- WHF $45.74
- TIL N/A
- Revenue Growth
- WHF N/A
- TIL N/A
- 52 Week Low
- WHF $6.57
- TIL $10.80
- 52 Week High
- WHF $12.18
- TIL $48.60
- Technical
- Relative Strength Index (RSI)
- WHF 27.83
- TIL 40.22
- Support Level
- WHF $8.70
- TIL $17.38
- Resistance Level
- WHF $8.97
- TIL $19.50
- Average True Range (ATR)
- WHF 0.29
- TIL 1.60
- MACD
- WHF -0.09
- TIL 0.04
- Stochastic Oscillator
- WHF 18.03
- TIL 34.90
About WHF WhiteHorse Finance Inc.
WhiteHorse Finance Inc is a non-diversified, closed-end management investment company. It makes debt investments in privately held; small-cap companies located in United States. Its investment objective is to generate risk-adjusted returns by originating and investing in senior secured loans, including first lien and second lien facilities, to performing lower middle market companies across a range of industries.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.